Hamilton Thomas Edward purchased $187K of LRMR (indirect holdings)

Hamilton Thomas Edward purchased 70,000 indirectly-held shares of Larimar Therapeutics, Inc. (LRMR) at $2.67 ($0.19M total) on 2026-11-12.

Original reporting
SEC EDGAR · Hamilton Thomas Edward
Published Nov 13, 2026, 2:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 2:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LRMR
Bullish
medium confidence
Mentioned
$LRMR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LRMRBullishLow
01

Why it matters

The filing provides new, primary information about insider activity, but the monetary amount is modest.

02

Market read

A small insider purchase that may generate slight positive sentiment but unlikely to affect price materially.

03

What to watch

If the director has additional undisclosed stakes or upcoming milestones, the purchase could be more meaningful.

Relevance 5/10Novelty 4/10Timing: after-hours filing

Background

SEC Form 4 filing discloses insider transactions. This is the first public report of the director's purchase.

Company-level read

Ticker impact

$LRMRBullishMedium confidence
Context

Director Hamilton Thomas Edward purchased 70,000 shares of Larimar Therapeutics at $2.6726, increasing his holding to 70,000 shares.

Expected impact

likely modest upward pressure as the market prices in the insider purchase

Evidence & confidence

The purchase is small relative to market cap but signals insider confidence, which can attract short-term buyers.

Market effects

Minimal impact on the broader biotech sector; only a single insider transaction.

Limited to US markets where LRMR trades.

Low global relevance.

Counterpoint

The purchase size is too small to move the stock; investors may ignore it.

Key entities

  • Larimar Therapeutics, Inc.

    Biotech company developing therapies for rare diseases.

  • Hamilton Thomas Edward

    Director of Larimar Therapeutics who made the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LRMRMed

Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update • Completed BLA submission seeking accelerated approval of nomlabofusp for adults and pediatric patients with FA; potential to be the first disease-modifying therapy to address root cause o

$LRMRMed

Larimar Therapeutics, Inc. (LRMR): Results of Operations and Financial Condition

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia • Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the under

$LRMRMed

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update • Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinica

$LRMRMed

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Larimar Therapeutics (NASDAQ:LRMR) filed the first module of its Biologics License Application with the U.S. FDA for Nomlabofusp therapy on an accelerated basis, with additional modules planned in the second half of 2026. The company cited positive open-label study results in adult Friedreich’s ataxia patients and said FDA confirmed existing data supports the submission using skin frataxin as a surrogate endpoint. Baird cut its price target to $5 from $7 while keeping an Outperform rating.